A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 329-336

  Heidenreich, A ^a,j   Rawal, S K ^b   Szkarlat, K ^c   Bogdanova, N ^d   Dirix, L ^e   Stenzl, A ^f   Welslau, M ^g   Wang, G ^g   Dawkins, F ^h   de boer, C J ^g   Schrijvers, D ⁱ  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

^c Urological Ward   (Poland)

^d P A Herzen Research Oncological Institute   (Russian Federation)

^e GZA Hospitals St   (Belgium)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g Studienzentrum ^*  (Netherlands)

^h JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

ⁱ Hospital Network Antwerp (ZNA) Middelheim   (Belgium)

^j RWTH AACHEN UNIVERSITY   (Germany)

more..

Author keywords

Alpha integrins; CRPC; Docetaxel; Intetumumab; Phase 2; Prostatic neoplasms

Indexed keywords

DOCETAXEL; INTETUMUMAB; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ELECTROCORTICOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; INFUSION RELATED REACTION; LEUKOPENIA; LIVER FUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SPINAL CORD COMPRESSION; STOMACH ULCER; TACHYCARDIA; URINARY TRACT INFECTION; UVEITIS; VOMITING;

EID: 84873843972     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds505     Document Type: Article

References (22)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
3. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583.
4. Garmey EG, Sartor O, Halabi S et al. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008; 6: 118-122, 127-132.
5. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
6. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
7. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
8. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
9. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
10. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-1230.
11. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-1502.
12. Mitjans F, Meyer T, Fittschen C et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 2000; 87: 716-723.
13. Trikha M, Zhou Z, Nemeth JA et al. CNTO 95, a fully human monoclonal antibody that inhibits alpha v integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004; 110: 326-335.
14. Chu FM, Picus J, Fracasso PM et al. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human alpha(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs 2011; 29: 674-679.
15. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
17. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
18. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-299.
19. Cleeland CS. Measurement of pain by subjective report. In Chapman CR, Loeser JD (eds), Advances in Pain Research and Therapy, New York: Raven Press 1989; 391-403.
20. Rosenthal MA, Davidson P, Rolland F et al. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 2010; 6: 42-48.
21. Bradley DA, Daignault S, Ryan CJ et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs 2011; 29: 1432-1440.
22. Slack-Davis JK, Parsons JT. Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 2004; 91: 41-46.